Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Curcuma domestica extracts is an investigational botanical product developed by researchers at Mahidol University's Faculty of Medicine Siriraj Hospital for the treatment of knee osteoarthritis. The active component consists of curcuminoid extracts derived from the dried rhizomes of *Curcuma domestica* (turmeric), which are processed via ethanol extraction and subsequent removal of oil components to yield a standardized extract. In Phase 3 clinical trials, the extract demonstrated efficacy comparable to ibuprofen in reducing pain and improving functional outcomes in patients with knee osteoarthritis, while exhibiting a superior gastrointestinal safety profile. Its mechanism of action is attributed to the anti-inflammatory properties of curcuminoids, which inhibit key inflammatory mediators including cyclooxygenase (COX), lipoxygenase (LOX), and various pro-inflammatory cytokines.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on curcuma domestica extracts.